Safety And Efficacy Of Oral PF-4136309 In Patients With Chronic Hepatitis C Infection And Abnormal Liver Enzymes

Status:
Terminated

Trial end date:
2012-02-01

Target enrollment:

Participant gender:

This study will evaluate the effect of PF-04136309 in patients with chronic hepatitic C virus infection and abnormal liver enzymes.

Phase 2

Pfizer